Weill Cornell Medicine researchers will explore novel combination therapies to address the gap in treatment options for patients with advanced urinary tract cancers. The study aims to understand how inherited genetic alterations and tumor-acquired mutations cooperate to disrupt DNA repair and drive cancers of the urinary tract.
Family physicians experiencing burnout are more likely to change practices or stop practicing entirely, with 43.5% reporting burnout in a recent study. This can lead to poorer patient outcomes, including increased ER visits and lower care satisfaction.
Six Weill Cornell Medicine researchers have been awarded Young Investigator Awards by the Prostate Cancer Foundation to investigate prostate cancer at a molecular level and develop new therapies. Drs. Bashir Al Hussein Al Awamlh, Cheuk Man Cherie Au, Lise Brault, Xuanrong Chen, Kevin Kensler, and Silvia Rodrigues will focus on improvin...
Dr. Y. Michael Shim has been named chief of the Division of Pulmonary and Critical Care Medicine, expanding access to comprehensive care for patients with chronic lung conditions. He will lead research and education efforts, including developing innovative imaging technologies to better understand lung disease.
A new AI-powered method predicts peak oxygen consumption with high accuracy, identifying high-risk patients with advanced heart failure. The study's multi-modal model uses cardiac ultrasound images and electronic health records to detect this critical measure.
Researchers found that dual-positive cells, a type of circulating tumor cell, are associated with shorter survival times and increased risk of metastasis in patients with advanced breast cancer. The study highlights the potential importance of these under-studied cells in breast cancer progression.
A Weill Cornell Medicine study found that prior exposure to one flu strain can weaken children's ability to mount an effective antibody response against a different strain, a phenomenon known as immune imprinting. This can lead to reduced effectiveness of future vaccines and increased risk of severe illness.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
Researchers from Weill Cornell Medicine found that state laws prohibiting private insurance from requiring prior authorization for buprenorphine did not significantly improve treatment retention. Despite a decrease in opioid overdose deaths, nearly 55,000 people still died from opioid overdose in 2024.
A machine-learning model developed by Weill Cornell Medicine predicts preeclampsia risk in late pregnancy with high accuracy. The model uses electronic health record data to continuously update risk predictions, potentially providing clinicians with timely clinical action.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
Researchers have successfully isolated and grown authentic reservoir clones (ARCs) that evade the immune system, providing new insights into how to eliminate them. The study suggests that potent CTLs can catch these cells during brief windows of HIV visibility, slowly shrinking the reservoir.
A large-scale study found that patients taking tirzepatide had a significantly lower risk of developing new diabetic retinopathy or progressing to more severe stages. This suggests that the medication may not worsen eye health, offering relief for patients concerned about their vision.
Researchers at Weill Cornell Medicine discovered that food shortages trigger a coordinated system to uphold immune function while conserving energy. Calorie-restricted mice fought off infection using very little glucose, thanks to glucocorticoids, which reorganized immune cells and their energy usage.
Two Weill Cornell physician-scientists, Dr. Semra Etyemez and Dr. Jesse Platt, have been awarded prestigious early-career awards from the American Society for Clinical Investigation (ASCI) for their outstanding research in obstetrics and gynecology, psychiatry, and gastroenterology. The ASCI recognizes and supports the scientific effor...
Dr. George Coukos, a leading authority on tumor immunology and cellular immunotherapy, joins Weill Cornell Medicine to lead the Ludwig Laboratory for Cell Therapy.
Researchers found that certain gut bacteria can deplete amino acids, affecting tumor growth or activating immune cells. Tailoring diets and microbiome strategies may enhance anti-tumor activity and support personalized therapy.
Researchers found that TL1A, a key immune signaling protein, stimulates the growth of new white blood cells in the bone marrow, which then promote tumor formation in the gut. The study suggests that blocking TL1A activity could be an effective strategy to treat IBD and prevent associated colorectal tumors.
Researchers are developing a comprehensive approach to diagnosing lymphatic disease, which is challenging due to the system's tiny and translucent vessels. The team aims to create a diagnostic toolbox that includes biomarkers, genetic analysis, and advanced detection technologies.
A recent national survey found that 88% of adults view opioid overdose deaths as a serious problem, but political differences over responsibility persist. The study suggests that more people are placing blame on pharmaceutical companies and individuals, rather than those who use opioids.
Researchers developed a technology to map pre-malignant gene mutations and their effects in solid tissues, finding over half of cells contained clonal driver mutations. The study used esophageal tissue samples from six older adults, discovering NOTCH1 and TP53 driver mutations that induced clonal overgrowth and impaired cell development.
Researchers developed an algorithm using whole-genome sequencing to detect homologous recombination deficiency, a type of DNA-repair defect vulnerable to PARP inhibitors. The approach identified genetic mutations beyond BRCA1 and BRCA2, promising more accurate patient selection for cancer treatment.
A new study reveals that Cornell prime dots, ultrasmall fluorescent particles, can reprogram the tumor microenvironment to make it more responsive to treatment. The nanoparticles induce anti-tumor effects by stimulating innate immune responses and reprogramming key immune cells.
Researchers found that pain-sensing neurons activate tuft cells, which release parasite-fighting immune molecules, initiating an immune response. Silencing or removing these neurons reduces tuft cell numbers, indicating their crucial role in fighting parasites and potentially driving allergic diseases.
A new study reveals that mature B cells temporarily gain plasticity during the antibody-making process, which could explain how many lymphomas develop from mature B cells. Researchers discovered that this epigenetic change is tightly regulated and can be hijacked by specific mutations to promote lymphomagenesis.
A large study found that women who underwent bypass surgery had a lower risk of major cardiovascular events and mortality compared to those who received stenting. However, women who underwent stenting had a slightly lower stroke risk.
Midbrain dopamine neurons create a glycogen fuel reserve but regulate it in a way that leaves them vulnerable to glucose shortages as they age. This vulnerability may explain the deaths of these neurons in Parkinson’s disease.
A new study from Weill Cornell Medicine reveals distinct patterns of brain activity between boys and girls with a family history of substance use disorder, suggesting separate predispositions for addiction. Girls with a family history displayed higher transition energy in the default-mode network, indicating greater difficulty disengag...
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
Weill Cornell Medicine researchers have discovered a molecular signal that tumors exploit to exhaust T cells meant to destroy them. By silencing this signal, the body's immunity can be revived and cancer-fighting immune cells restored.
A preclinical study from Weill Cornell Medicine investigators found that hypertension impairs blood vessels, neurons and white matter in the brain before causing a measurable rise in blood pressure. Gene expression changes in individual brain cells could interfere with thinking and memory.
A Weill Cornell Medicine investigator outlines measures to ensure children's health is accounted for within climate change goals. The author suggests adopting 17 standardized indicators related to childhood mortality rates, nutrition, and vaccination coverage to support other targets like the Sustainable Development Goals.
Researchers pinpointed the source of free radicals in non-neuronal brain cells that may fuel dementia. Blocking this site lowers brain inflammation and protects neurons, suggesting a novel therapeutic approach for neurodegenerative disorders.
Researchers at Weill Cornell Medicine have developed a powerful new gene-switch tool called Cyclone, which allows scientists to turn on or off target genes with precision. The tool uses a non-toxic molecule acyclovir to suppress gene activity, and has the potential to be adopted throughout biomedical research and gene therapies.
Researchers warn that Medicaid funding cuts will have significant spillover effects on children's health due to a lack of consideration for their coverage. Experts suggest policies such as loan repayment and increased investment in pediatric workforce development can help mitigate the issue.
A new $4 million grant will support the establishment of a health economics research facility to evaluate and compare the economic value of available interventions in the criminal-legal system. The researchers aim to develop tools and resources for policymakers to identify strategic investments in substance use disorder care.
Researchers are building an AI-powered database of MRI and CT images to track disease progression and measure patient response to treatments. The database will provide a standardized toolkit for extracting precise imaging biomarkers, enhancing the accuracy of organ measurements and improving treatment choices.
Dr. Lauren Henderson, a pediatric rheumatologist, has been awarded the 10th annual Gale and Ira Drukier Prize in Children’s Health Research. Her research focuses on children with difficult-to-treat juvenile idiopathic arthritis and other autoimmune disorders, exploring how the immune system goes awry in these conditions.
Researchers at Weill Cornell Medicine develop a new method to generate functional endothelial cells from adult tissue, potentially enabling vascular grafts and organ transplants. The approach involves using small molecules to trigger cell division without aging or losing function.
A new multi-omics tool, GoT-Multi, has enabled researchers to gain insights into how cancers evolve towards greater aggressiveness and therapy resistance. The tool can analyze diverse types of pathology samples and quickly process large numbers of cells, revealing new details about cancer progression.
Researchers discovered that an enzyme called EZH2 drives triple negative breast cancer cells to divide abnormally, enabling them to spread. Inhibiting EZH2 with drugs like tazemetostat restored order to dividing cells and thwarted the spread of TNBC cells.
The AR² Center will replicate, validate and reproduce existing autism research results using various data sets. The center aims to foster public trust in the field by providing transparent communication of scientific findings.
Researchers developed a molecular tool called SCOPE that can capture proteins binding to DNA, enabling identification of protein regulators. The tool was used to discover new protein regulators of human stem cell-related genes, revealing the roles of two proteins in maintaining stem cells and one in inducing differentiation.
A successful HIV vaccine could be a major public health breakthrough, preventing 1.3 million new infections in 2024 and saving lives from the virus. The new childhood vaccine is based on the Env trimer protein complex and aims to elicit broadly neutralizing antibodies in young immune systems.
Dr. Carl Nathan's groundbreaking research has advanced our understanding of innate immunity, tuberculosis, and cancer. His discovery of macrophage-activating factor (MAF) and its role in driving immune responses has led to the development of new treatments for previously intractable diseases.
A four-year NIH grant will support a study of type 1 diabetes, led by Dr. Shuibing Chen at Weill Cornell Medicine. The researchers will investigate the interplay between genetic and environmental triggers using advanced laboratory and computational tools.
A new preclinical study from Weill Cornell Medicine suggests that inflammation during pregnancy may prime offspring for anxiety. The researchers discovered that adversity in the womb configured a small percentage of brain cells to be overly active when faced with a threatening situation, creating a vulnerability to anxiety.
Ana Campos Codo, a Weill Cornell Immunology and Microbial Pathogenesis Ph.D. student, has been selected for the 2025 cohort of the HHMI Gilliam Fellows Program. The program provides $65,000/year support for up to three years to students and their faculty thesis advisors.
A new study published in JAMA Network Open found that older adults living in flood-hit areas in New Jersey faced a 5% higher risk of heart disease for up to five years after Hurricane Sandy's landfall. Flooded ZIP code areas had lower median incomes and higher area deprivation index scores, which are linked to worse health outcomes.
A scientific team co-led by Dr. Lishomwa Ndhlovu at Weill Cornell Medicine has received an NIH MERIT Award to study a handful of people who have managed to clear HIV after a stem cell transplant. The goal is to identify the immune mechanisms that led to remission and develop a broadly applicable immunotherapy for eliminating HIV.